Harrow and iOR Partners have expanded their national product supply agreement, according to a press release.
Harrow will provide its entire formulary of compounded ophthalmic products to iOR Partners for the company’s expanding office-based surgery locations across the U.S.
The agreement will allow Harrow’s ophthalmic surgery products, including MKO Melt (midazolam, ketamine HCl, ondansetron), which reduces the use of opioids and needles, to be implemented into office-based procedures.
“iOR Partners assists practices nationwide to make office-based ophthalmic surgery a reality,”